Contracts › 75A50119C00061
75A50119C00061: This Contract Is to Advance the Development of Romiplostim for Treatment of Hematopoietic Subsyndrome-Acute Radiation Syndrome (HS-ARS) and Chemotherapy-Induced Thrombocytopenia (CIT) and a Drug Delivery Device Feasibility Project With an Option to
Awarded to Amgen Inc. by Office of Assistant Secretary for Preparedness and Response.
$26.4Mobligated
$33.7Mpotential value
31 December 2027current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75A50119C00061 |
|---|---|
| Awardee | Amgen Inc. |
| Awarding agency | Office of Assistant Secretary for Preparedness and Response |
| Awarding office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 Research and Development in Biotechnology (Except Nanobiotechnology) |
| PSC | AN73 R&D- Medical: Specialized Medical Services (Advanced Development) |
| Place of performance | CA |
| Offers received | 1 |
| Period of performance | 26 September 2019 to 31 December 2027 |
| Potential end | 31 December 2027 |
| Estimated recompete solicitation | ~Q3 2027 (estimate, ~6 months before expiry) |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 04 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541714 contracts · All expiring contracts · USASpending record